Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.

@article{Ekert2001CostutilityAO,
  title={Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.},
  author={Henry Ekert and Trauma Brewin and W Boey and Peter Davey and Dominic P. Tilden},
  journal={Haemophilia : the official journal of the World Federation of Hemophilia},
  year={2001},
  volume={7 3},
  pages={279-85}
}
The high cost of treating patients with inhibitors in an environment of restricted budgets warrants consideration of cost-effectiveness. We determined the clinical response, effect on quality of life and the cost-effectiveness of treatment with rFVIIa in six boys with long-standing inhibitors to factors VIII or IX, compared with other treatment regimes previously used in these patients. The study used a longitudinal before-and-after design and was conducted in three phases. Phase 1 was 6 months… CONTINUE READING
17 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…